DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma

Clinical Cancer Research

Volumn 16, Issue 7, 2010, Pages 1997-2008

  Kuo, Kuan Ting ^a,b   Mao, Tsui Lien ^b   Chen, Xu ^a,c   Feng, Yuanjian ^d   Nakayama, Kentaro ^e   Wang, Yue ^d   Glas, Ruth ^f   Ma, M Joe ^g   Kurman, Robert J ^a   Shih, Ie Ming ^a   Wang, Tian Li ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d State University   (United States)

^e SHIMANE UNIVERSITY   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER THERAPY; CHROMOSOMAL INSTABILITY; CHROMOSOME 20; CLEAR CELL CARCINOMA; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; GENE MUTATION; GENOME; GROWTH INHIBITION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; ONCOGENE; OVARY CARCINOMA; PIK3CA GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ZNF217 GENE;

ADENOCARCINOMA, CLEAR CELL; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; CHROMOSOMAL INSTABILITY; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICROARRAY ANALYSIS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANS-ACTIVATORS;

EID: 77950687396     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2105     Document Type: Article

References (46)

1. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis 2009;4: 287-313.
2. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, editor. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York: Springer Verlag; 2002, p. 791-904.
3. Scully RE. World Health Organization International Histological Classification of Tumours. 2nd ed. New York (NY): Springer; 1999.
4. Scully RE. International histological classification of tumors: Histological typing of ovarian tumors. Geneva: World Health Organization; 1999.
5. Veras E, Mao TL, Ayhan A, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol 2009;33:844-853
6. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997;30:249-255
7. Erzen M, Rakar S, Klancnik B, Syrjanen K. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001;83:100-108
8. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006;94:1369-1374
9. Mizuno M, Kikkawa F, Shibata K, et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 2006;94:138-143
10. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 2008;109:370-376
11. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102:285-291
12. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-417
13. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589
14. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007;105:404-408
15. Takano M, Sugiyama T, Yaegashi N, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 2008;18:937-942
16. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174: 1597-1601
17. Shih Ie M, Wang TL. Apply innovative technologies to explore cancer genome. Curr Opin Oncol 2005;17:33-38
18. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 1999;96:5722-5727
19. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004;10:1032-1042
20. Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC. Models of ovarian cancer - Are we there yet? Mol Cell Endocrinol 2005; 239:15-26.
21. Nakayama K, Nakayama N, Jinawath N, et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007;120:2613-2617
22. Kuo KT, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036-4042
23. Wang TL, Maierhofer C, Speicher MR, et al. Digital karyotyping. Proc Natl Acad Sci U S A 2002;99:16156-16161
24. Buckhaults P, Zhang Z, Chen YC, et al. Identifying tumor origin using a gene expression-based classification map. Cancer Res 2003;63: 4144-4149
25. Letessier A, Sircoulomb F, Ginestier C, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006;6:245.
26. Weiss MM, Snijders AM, Kuipers EJ, et al. Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol 2003;200:320-326
27. Caubit X, Tiveron MC, Cremer H, Fasano L. Expression patterns of the three Teashirt-related genes define specific boundaries in the developing and postnatal mouse forebrain. J Comp Neurol 2005; 486:76-88.
28. Collins C, Rommens JM, Kowbel D, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 1998;95:8703-8708
29. Cowger JJ, Zhao Q, Isovic M, Torchia J. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 2007;26:3378-3386
30. Hakimi MA, Dong Y, Lane WS, Speicher DW, Shiekhattar R. A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J Biol Chem 2003;278:7234-7239
31. Nancarrow DJ, Handoko HY, Smithers BM, et al. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2008;68:4163-4172
32. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-13 in ovarian cancer. Clin Cancer Res 2000;6:1833-1839
33. Suzuki S, Egami K, Sasajima K, et al. Comparative study between DNA copy number aberrations determined by quantitative microsatellite analysis and clinical outcome in patients with stomach cancer. Clin Cancer Res 2004;10:3013-3019
34. Quinlan KG, Verger A, Yaswen P, Crossley M. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta 2007;1775:333-340
35. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001;61:1250-1254
36. Huang G, Krig S, Kowbel D, et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 2005;14:3219-3225
37. Li P, Maines-Bandiera S, Kuo WL, et al. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer 2007;120:1863-1873
38. Suehiro Y, Sakamoto M, Umayahara K, et al. Genetic aberrations detected by comparative genomic hybridization in ovarian clear cell adenocarcinomas. Oncology 2000;59:50-56
39. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001;91:534-540
40. Dent J, Hall GD, Wilkinson N, et al. Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 2003;88:1578-1583
41. Ishii H, Baffa R, Numata SI, et al. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci U S A 1999;96:3928-3933
42. Ishii H, Vecchione A, Murakumo Y, et al. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci U S A 2001;98:10374-10379
43. Vecchione A, Baldassarre G, Ishii H, et al. Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell 2007;11:275-289
44. Shih I-M, Kurman RJ. Ovarian tumorigenesis - a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-1518
45. Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005;11:7273-7279
46. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198:351-356